Measles pp 3-11 | Cite as

John F. Enders and Measles Virus Vaccine—a Reminiscence

Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 329)

Following their initial isolation in cell culture of the virus in 1954, a succession of investigators under the mentorship of John F. Enders conducted the research, development, and initial clinical studies responsible for the licensure in 1963 of a successful live attenuated measles virus vaccine. Propagation of the virus successively in human kidney cells, human amnion cells, embryonated hens' eggs, and finally chick embryo cell cultures had selected virus that when inoculated into susceptible monkeys proved immunogenic without viremia or overt disease, in contrast to the early kidney cell-passaged material, which in similar monkeys produced viremia with illness mimicking human measles. Careful clinical studies in children by the Enders group and then by collaborating investigators in many sites established its safety, immunogenicity, and efficacy. This Edmonston strain measles virus became the progenitor of vaccines prepared, studied, and utilized throughoutthe United States and many other countries. With appreciation of measles morbidity and mortality, most marked among infants and children in the resource-limited lands, the vaccine was incorporated into the World Health Organization's (WHO) Expanded Programme of Immunization (EPI) in 1974 along with BCG, OPV, and DTP. Successful efforts to further reduce measles' burden were launched in 2001 and are continuing as the Measles Initiative (Partnership) under the leadership of the American Red Cross, International Red Cross, and Red Crescent societies, Centers for Disease Control (CDC), United Nations Children's Fund (UNICEF), WHO, and the United Nations Foundation.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Annunziato D, Kaplan MH, Hall WW, Ichinose H, Lin JH, Balsam D, Paladino VS (1982) Atypical measles syndrome: pathologic and serologic findings. Pediatrics 70:203–209PubMedGoogle Scholar
  2. Bellini WJ, Rota JS, Lowe LE (2005) Subacute sclerosing panencephalitis: more cases of this diseases are prevented by measles immunization than was previously recognized. J Infect Dis 192:1684–1693CrossRefGoogle Scholar
  3. de Quadros CA, Izurieta H, Venczel L, Carrasco P (2004) Measles eradication in the Americas:progress to date. J Infect Dis (Suppl 1) 189:S227–S235PubMedCrossRefGoogle Scholar
  4. Enders JF, Peebles TC (1954) Propagation in tissue culture of cytopathogenic agents from patients with measles. Proc Soc Exp Biol Med 86:277–286PubMedGoogle Scholar
  5. Enders JF, Katz SL, Milovanovic M V, Holloway A (1960) Studies on an attenuated measles-virus vaccine. I. Development and preparation of the vaccine: technics for assay of effects of vaccination. New Eng J Med 263:153–159PubMedGoogle Scholar
  6. Enders JF, Katz SL, Holloway A (1962) Development of attenuated measles virus vaccines. Asummary of recent investigations. Am J Dis Child 103:335–340PubMedGoogle Scholar
  7. Fulginiti VA, Eller JJ, Downie AW, Kempe CH (1967) Altered reactivity to measles virus: atypical measles in children previously immunized with inactivated measles virus vaccines. JAMA 1075–1080Google Scholar
  8. Horta-Barbosa L, Fucillo DA, Sever JL, Zevan W (1969) Subacute sclerosing panencephalitis: isolation of measles virus from a brain biopsy. Nature 221:974PubMedCrossRefGoogle Scholar
  9. Katz SL (2005) A vaccine-preventable disease kills half a million children annually. J Infect Dis 192:1679–1680PubMedCrossRefGoogle Scholar
  10. Katz SL, Enders JF (1959) Immunization of children with a live attenuated measles virus. Am J Dis Child 98:605–607Google Scholar
  11. Katz SL, Hinman AR (2004) Summary and conclusions measles elimination meeting, 16–17 March 2000. J Infect Dis (Suppl 1) 189:S43–S47PubMedCrossRefGoogle Scholar
  12. Katz SL, Milovanovic M V, Enders JF (1958) Propagation of measles virus in cultures of chick embryo cells. Proc Soc Exp Biol Med 97:23–29PubMedGoogle Scholar
  13. Katz Sl, Enders JF, Holloway A (1960a) Studies on an attenuated measles-virus vaccine. Clinical,virologic and immunologic effects of vaccine in institutionalized children. New Eng J Med 263:159–161Google Scholar
  14. Katz SL, Kempe CH, Black FL, Lepow ML, Krugman S, Haggerty RJ, Enders JF (1960b) Studies on an attenuated measles-virus vaccine. VIII. General summary and evaluation of the results of vaccination. New Eng J Med 263:180–184Google Scholar
  15. Katz SL, Morley DC, Krugman S (1962) Attenuated measles virus vaccine in Nigerian children. Am J Dis Child 103:402–405PubMedGoogle Scholar
  16. Milovanovic MV, Enders JF, Mitus A (1957) Cultivation of measles virus in human amnion cells and developing chick embryo. Proc Soc Exp Biol Med 95:120–127PubMedGoogle Scholar
  17. Payne FE, Baublis JV, Itahashi HH (1969) Isolation of measles virus from cell cultures of brain from a patient with subacute sclerosing panencephalitis. New Eng J Med 281:585–589PubMedGoogle Scholar
  18. Peebles T, McCarthy K, Enders JF, Holloway A (1957) Behavior of monkeys after inoculation of virus derived from patients with measles and propagated in tissue culture. J Immunol 78:63–74PubMedGoogle Scholar
  19. Rauh LW, Schmidt R (1965) Measles immunization with killed virus vaccine. Am J Dis Child 109:232–237PubMedGoogle Scholar
  20. Wolfson LJ, Strebel PM, Gacic-Dobo M, Hoekstra EJ, McFarland JW, Hersh BS (2007) Has the 2005 measles mortality reduction goal been achieved? Lancet 369:191–200PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  1. 1.Duke University Medical CenterDurhamUSA

Personalised recommendations